The “plausible mechanism pathway” will allow personalised drugs to reach the market sooner for patients with genetic diseases ...

Poherdy is the first FDA-approved interchangeable biosimilar to Perjeta for HER2-positive breast cancer, potentially expanding access and reducing costs. Approved for use in combination with ...

Consolidates messaging around Einstein Rx AI, Wellgistics Hub (formerly DelivMeds) and HubRx AI integration with pharmacies (in-house pharmacy and 6,500+ independent pharmacy network), physicians and ...

Clinical development programs for doxorubicin-containing microneedle array (D-MNA) and Teverelix, a next generation GnRH ...

The smart thermometer performs a check-up on your body temperature, cardiac, and pulmonary health in less than a minute.

OBESITY IS A SERIOUS PROBLEM IN OUR STATE. AND DRUGS TO TREAT IT ARE EXPENSIVE. NOW SOME GROUPS ARE ASKING THE GOVERNOR TO ...

SynchNeuro is a Portfolio Company of Boomerang Ventures INDIANAPOLIS, IN / ACCESS Newswire / November 12, 2025 / Boomerang Ventures adds SynchNeuro, Inc. to its portfolio of seed-stage investments, ...

Through substantial leadership turnover and workforce cuts, the FDA has continued to support the advanced therapy sector, actively working to remove obstacles to innovation.

As deadly drug overdoses climbed across Canada, decision-makers faced political backlash for funding programs that gave drug ...

While AI has accelerated drug discovery, the same technology can address clinical trial bottlenecks that have persisted for ...

The FDA has removed a long-standing black box warning from menopause hormone therapies. This decision reverses decades of ...

House Bill 324 would ban mail-order sales of certain medications and require in-person doctor visits. Abortion rights ...